Discover key takeaways from Bruker Corporation's Q4 2024 earnings call, highlighting strong diagnostics, semiconductor growth, and confident 2025 ...

Corporation reported its fourth-quarter 2024 earnings, surpassing analysts' expectations with an earnings per share (EPS) of $0.76 against the forecast of $0.74. Revenue also exceeded projections, ...

Bruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2024. Frank H. Laukien, Bruker's ...

Scientific instrument company Bruker (NASDAQ:BRKR). reported Q4 CY2024 results exceeding the market’s revenue expectations, ...

MedPharm DBA Bud & Mary's, a federally licensed cannabis research and pharmaceutical development company, continues to lead scientific advancements in cannabis-based therapeutics as the only U.S.

Scientific instrument company Bruker (NASDAQ:BRKR). will be reporting results tomorrow before market hours. Here’s what ...

Bruker (NASDAQ:BRKR – Get Free Report) had its price target lowered by stock analysts at Barclays from $69.00 to $65.00 in a research note issued on Monday,Benzinga reports. The firm currently has an ...

In a stark reflection of the challenges facing the biotech sector, 10X Genomics Inc (NASDAQ:TXG) stock has tumbled to a 52-week low, touching down at $11.89. According to InvestingPro data, technical ...

Browse 400 market data Tables and 50 Figures spread through 250 Pages and in-depth TOC on "Mass Spectrometry Market by ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...

The Mass Spectrometry market valued at US$ 5.82 Billion in 2023, is forecasted to grow at a robust CAGR of 7.2%, reaching US$ ...

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales reorganization and grow base of industry users.